CN
GV20 ONCOTHERAPY
GV20 Oncotherapy was started by an expert team trained at world-renowned universities. We are devoted to precision medicine development in cancer immuno-oncology. GV20 Oncotherapy has innovative antibody drug discovery and development platforms that integrate cancer genomics, immuno-oncology, and artificial intelligence. We are utilizing our technological advantages to search novel immunotherapy targets, screen fully human anti-tumor antibodies, and identify robust clinical biomarkers.
Technology platforms
Novel Immuno-Oncology Targets
Tumor-Specific Fully Human Antibodies
Robust Response Biomarkers
Atlas Genomics PlatformTumor profile,CRISPR screen &
antibody screen
Phial AI PlatformBig data & machine learning algorithms
investors
  • Linear Capital

  • IDG

  • WATSON

China
Address:Room 801, 781 Cailun Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, China
Email:bd@bioxbh.com
USA
Address:One Broadway, 14th floor, Kendall Square, Cambridge, MA 02142, USA
Email:hr@gv20therapeutics.com